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Role of axillary ultrasound in the 
evaluation of early breast cancer in the 
era of Z0011: Time to redefine?
AbstRAct
Introduction: Ultrasound with concurrent histology of abnormal axillary lymph nodes has revolutionized the 
treatment of patients with breast cancer. By identifying nodal metastases, patients can avoid a two-stage 
axillary procedure. However, the results of the American College of Surgeons Oncology Group Z0011 trial 
indicate that a certain group of patients may have been over-treated with axillary dissection. Our aim was 
to analyze the nodal burden of patients identified by axillary ultrasound and to determine the proportion 
of patients who could have foregone axillary dissection incorporating Z0011 trial.
Methods: A retrospective analysis of patients with diagnosed breast cancer who underwent direct axillary 
dissection was performed. Based on nodal metastases patients were categorized into ‘extensive’ and 
‘minimal’ groups and studied. Demographics and tumor characteristics were analyzed and eligibility for 
the Z0011 study was determined.
Results: All 1745 patients diagnosed with breast cancer underwent axillary ultrasound from April 2009 to 
March 2015. Of these, 197 patients had histology-proven nodal metastases and underwent direct axillary 
lymph node dissection. One hundred and twenty-one patients (61.4%) had extensive and 76 patients 
(38.6%) had minimal nodal metastases. Of the latter, 23 patients (11.7%) fulfilled the Z0011 criteria. 
Conclusion: This study demonstrated that a large proportion of patients had minimal nodal involvement 
(38.6%), in contrast to the results published in the literature. In addition, a significant number of patients 
could have avoided axillary dissection (11.7%) based on the Z0011 criteria. Hence our study encourages 
to redefine the role of axillary ultrasound to avoid unnecessary axillary dissection.
Key points:
1. Axillary ultrasound is performed in all patients diagnosed with breast cancer.
2. Axillary ultrasound findings do not correlate with histological burden of nodal disease.
3. Role of axillary ultrasound needs to be redefined to avoid unnecessary axillary dissection.
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Introduction 
Axillary ultrasound combined with fine needle 
aspiration cytology (FNAC) or core biopsy (CB) has 
established its role as an accurate tool for identifying 
axillary nodal metastasis. This procedure identifies 
approximately 50% of nodal involvement pre-opera-
tively [1]. In the United Kingdom, axillary ultrasound is 
customarily performed for all patients diagnosed with 
breast cancer, as recommended by the National Insti-
tute for Health and Care Excellence (NICE) [2]. If nodal 
involvement is detected by a combination of ultrasound 
and FNAC/CB, direct axillary lymph node dissection 
(ALND) is performed. 
If axillary ultrasound is unable to identify nodal 
metastatic disease, sentinel lymph node biopsy will be 
performed as the gold standard for staging of axillary 
disease [3–4].  ALND is then recommended as a sepa-
rate procedure if the sentinel node biopsy yields a pos-
itive result [5–6]. Axillary ultrasound therefore facilitates 
patients to undergo a direct single stage axillary dissec-
tion rather than this two-stage procedure. This reduces 
patient morbidity and generates financial benefits for 
the healthcare system [7]. However, axillary ultrasound 
may prove to be a double-edged sword, leading to an 
over-treatment of axillary disease associated with its 
significant morbidities [8–9]. This is because various 
studies have demonstrated that the sentinel lymph node 
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was the only positive lymph node in 40–60% of patients 
[10–11] and also nomograms have been validated to 
identify patients who are at risk of non-sentinel lymph 
node metastasis [12–14]. More importantly, the results 
of the American College of Surgeons Oncology Group 
(ACOSOG) Z0011 trial published earlier in 2011 and 
recently updated in 2017 suggest that a subgroup of 
patients can safely avoid ALND after positive sentinel 
lymph node biopsy [15–16]. In this trial, patients with 
a tumor size less than 5 cm who also had one or two 
positive sentinel nodes (without matting or extra nodal 
extension) were treated with breast-conserving surgery 
and whole breast irradiation. This study had a median 
follow up of 9.25 years and found no difference in the 
overall survival [15] or locoregional recurrence [16] in 
patients who did or did not undergo axillary lymph node 
dissection after a positive sentinel lymph node biopsy. 
Despite some limitations [17–18], this study is the best 
available evidence to date with long term follow up, 
supporting the avoidance of ALND in a sub-group of 
patients [19–20]. 
The primary aim of our study was to assess the axil-
lary nodal burden from the histopathological findings of 
direct ALND and classify them into patients with minimal 
nodal involvement (≤ 2 positive nodes) and extensive 
nodal involvement (> 2 positive nodes). This study also 
aimed to identify which of our patients could have safely 
foregone ALND based on the findings of the Z0011 trial. 
Overall, we hoped to find features which may be pre-
dictive of minimal or extensive nodal involvement by 
analyzing the differences in tumor characteristics and 
outcomes between the two groups.
Material and methods 
Patients with primary breast cancer between 
April 2009 and March 2015 were identified from the 
surgical database of our hospital and retrospectively 
analyzed. Our departmental policy was to perform ax-
illary ultrasound on all patients with suspected breast 
cancer. Radiologists with an interest in breast, as well 
as trained clinical specialists, performed the axillary 
ultrasounds. Lymph nodes were deemed suspicious if 
they were multiple and large (> 1 cm), with eccentric 
or more than 2 mm cortical thickening and replacement 
or loss of the fatty hilum. 
Suspicious nodes identified using axillary ultrasound 
were sampled using FNAC or CB, at the operator’s 
discretion. Histopathological assessment of nodal 
samples was then performed using hematoxylin and 
eosin staining and an immunohistochemical profile 
was then generated upon identification of metastatic 
disease. Patients with axillary nodal metastatic disease 
underwent direct ALND, accompanied by wide local 
excision (WLE) or mastectomy as deemed clinically 
appropriate. 
Details regarding positive nodal disease from 
FNAC/CB following axillary ultrasound and further ALND 
were obtained from histopathological reports. Demo-
graphics and tumor characteristics were identified from 
multi-disciplinary discussions and clinical letters were 
used to follow-up significant events.
Histopathological data collected were size, type 
and grade of tumor, multifocality, lymphovascular 
invasion, HER2 status and the presence of estrogen 
and progesterone receptors. The number of nodes 
removed during ALND were recorded as well as the 
number of positive nodes to categorize into ‘minimal’ 
and ‘extensive’ groups.
We then identified which of these patients could 
have safely foregone axillary lymph node dissection 
based on the Z0011 criteria. This included patients who 
underwent breast conserving surgery for a tumor size 
less than 5 cm, had ≤ 2 positive nodes from axillary 
dissection without matting and extra-nodal extension 
and were treated with adjuvant whole breast irradiation. 
Patients who underwent preoperative neo-adjuvant 
treatment and who had a mastectomy as the definitive 
treatment were excluded. 
statistical analyses
All analyses were conducted with The Graph Pad 
software (Prism version 5). For numeric data, values are 
expressed in median with percentages and Chi squared 
analyses or a Fisher’s exact test were used to assess 
differences in patient and tumor characteristics between 
those with minimal nodal involvement (≤ 2 positive 
nodes) and extensive nodal involvement (> 2 positive 
nodes). A p value of ≤ 0.05 was considered significant.
Results
A total of 1745 patients were diagnosed with op-
erable breast cancer between April 2009 and March 
2015. Of these, 269 patients underwent direct ALND for 
axillary nodal metastases. Ten patients had undergone 
axillary dissection for recurrent breast cancer and were 
excluded. Twenty patients were excluded from the study 
because there were no clear indications for ALND in 
place of sentinel lymph node biopsy. Biopsies were 
not performed in 14 patients due to technical reasons, 
although these patients were highly suspicious for nodal 
metastases from axillary ultrasound. Three patients had 
an axillary dissection based on an abnormality in an-
other modality of imaging (CT, MRI and mammogram). 
Another four patients had axillary dissection based on 
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suspicion of nodal metastases intraoperatively. Twen-
ty-one patients had benign findings on FNAC/CB, but 
still received axillary dissection due to high suspicion 
from axillary ultrasound and were thus excluded. 
In total, seventy-two patients were excluded from the 
study, and the remaining 197 patients with definitive di-
agnosis of axillary nodal metastases on ultrasound and 
FNAC/CB who underwent direct ALND were ultimately 
considered eligible for the study as shown in Table 1.  
The median age of the patients was 62 years (range, 
23–92). All except one patient were female. Eighty-
five patients (43.1%) had breast-conserving surgery, 
while 112 patients (56.9%) underwent mastectomy. 
The median pathological tumor size was 24.5 mm 
(range, 5–130 mm). Fifty six of the 197 patients (28.4%) 
had T1 tumors, and 119 patients (60.4%) had T2 tu-
mors. Seventeen patients (8.6%) had a tumor greater 
than 50 mm, while multifocal disease was detected in 
12 patients (6%). Invasive ductal carcinoma was the 
predominant tumor upon final pathology (172 patients, 
87%), while invasive lobular carcinoma was observed 
in 23 patients (12%). Other pathologies were noted in 
two patients (medullary carcinoma). 
Grade 3 disease was found in 136 patients (69%), 
57 patients had grade 2 and only four patients had 
grade 1 disease. Lymphovascular invasion was pres-
ent in 103 patients (n = 193, 53.4%). The majority of 
patients were estrogen receptor (ER) positive (155, 
78.7%), while 55 (27.9%) were HER2 positive. Thirty-six 
patients (18.3%) were ER positive/HER2 positive, while 
23 patients (11.7%) were triple negative. 
Of the 197 patients, FNAC was diagnostic in 92 pa-
tients (C5 – 85; C4 – 5; C3 – 2), and a core biopsy 
confirmed metastases in the remaining 105 patients 
(B5 – 104; B4 –1). The median number of lymph nodes 
excised during axillary dissection was 15 (range, 4–35), 
and the median number of positive nodes was 3 (range, 
0–31). Five patients had no positive nodes upon axillary 
dissection. Within this group of patients, 76 patients 
(38.6%) had two positive nodes or less from ALND 
(minimal nodal metastases), and 121 patients had more 
than two positive nodes (extensive nodal metastases). 
The characteristics of these groups of patients are 
outlined in Table 1. 
There was no significant difference observed be-
tween the two groups in terms of age, type of surgery, 
tumor size, morphology, estrogen receptor status, 
HER2 status and multifocality. Differences in tumor 
grade, progesterone and triple-negative receptor 
status were borderline but not significant. However, 
the presence of lymphovascular invasion was sig-
nificant in patients with extensive nodal metastasis 
(P < 0.001).
The median follow-up was 4.6 years. A total of 
15 patients died during follow up; eight from the minimal 
Table 1. Characteristics of patients who had axillary 
clearance and grouped into minimal nodal and extensive 
nodal metastases
Patient 
characteristics
< 2 
Positive 
lymph 
nodes  
(n = 76)
> 2  
Positive 
lymph 
nodes  
(n = 121)
p value
Age
Median (Range)
< 50 years
50–69 years
= / > 70 years
 62 (23-90)
15 (19.7%)
37 (48.7%)
24 (31.6%)
62 (33–92)
32 (26.4%)
49 (40.5%)
40 (33.1%)
0.44
Type of surgery
Breast conserving
Mastectomy
38 (50.0%)
38 (50.0%)
47 (38.8%)
74 (61.2%)
0.14
Tumor size in mm
Median (Range)
< 20 mm
20–30 mm
> 30 mm
23 (5–60)
23 (30.3%)
35 (46.0%)
18 (23.7%)
26 (8–130)
33 (27.3%)
44 (36.4%)
39 (32.2%)
0.31
Morphology  
of tumor
Ductal carcinoma
Lobular carcinoma
Other types
70 (92.1%)
5 (6.6%)
1 (1.3%)
102 (84.3%)
18 (14.9%)
1 (0.8%)
0.08
Tumor Grade
Grade 1 
Grade 2
Grade 3
3 (3.9%)
23 (30.3%)
50 (65.8%)
1 (0.8%)
34 (28.1%)
86 (71.1%)
0.29
ER* status
Negative 
Positive
17 (22.4%)
59 (77.6%)
25 (20.7%)
96 (79.3%)
0.86
PR** status
Negative
Positive
37 (48.7%)
39 (51.3%)
49 (40.5%)
72 (59.5%)
0.30
Her2*** Status
Negative
Positive
57 (75%)
19 (25%)
85 (70.2%)
36 (29.8%)
0.52
Triple Negative
No
Yes
65 (85.5%)
11 (14.5%)
109 (90.1%)
12 (9.9%)
0.37
Multifocality
No 
Yes
70 (92.1%)
6 (7.9%)
115 (95%)
6 (5%)
0.54
Lymphovascular 
invasion
No 
Yes
Not recorded
52 (68.4%)
24 (31.6%)
0
51 (42.1%)
66 (54.5%)
4
0.001
Mortality follow up 
4–5yrs
Dead
Alive
8 (10.5%)
68 (89.5%)
7 (5.8%)
114 (94.2%)
0.27
*ER – Estrogen Receptor
**PR – Progesterone Receptor
***Her2 – Human Epidermal Growth Factor Receptor 
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Figure 1. Patient characteristics: distribution with respect 
to age
Figure 2. Tumor characteristics: distribution with respect 
to type of surgery
Figure 3. Tumor characteristics: distribution with respect 
to size of tumor
Figure 4. Tumor characteristics: distribution with respect 
to tumor morphology
Figure 5. Tumor characteristics: distribution with respect 
to grade of tumor
Figure 6. Tumor characteristics: distribution with respect 
to presence of lymphovascular invasion
nodal group and seven from the extensive nodal group 
with an overall survival rate of 89.5% and 94.2%, respec-
tively. There was no statistical significance between the 
two groups in terms of survival.  
Patients with minimal nodal involvement were poten-
tially eligible for the Z0011 study. Of these, 53 patients 
were excluded as they did not meet the criteria, the 
predominant cause being mastectomy as the definitive 
86
Medical research journal 2018, vol. 3, no. 2
www.journals.viamedica.pl/medical_research_journal
breast surgery. The remaining 23 patients (11.7%) satis-
fied the criteria for the Z0011 study, and could therefore 
have been spared axillary lymph node dissection.
Discussion
With advancement in technology and expertise in 
image interpretation, ultrasound has become a signifi-
cant preoperative tool in the evaluation of nodal disease.
Studies have shown that high-resolution ultrasound 
can detect nodal metastases in breast cancer with 
a sensitivity and specificity ranging from 50–70% and 
90–97.2%, respectively [21]. In conjunction with cytolo-
gy/histology, the literature demonstrates increase in sen-
sitivity and specificity to 80–90% and 100%, respectively, 
when conducted by experienced radiologists [22–23].
The improvement in ultrasound examination sug-
gests that the chance of finding axillary metastases will 
increase. This means that more patients who would 
have otherwise had a sentinel lymph node biopsy 
will instead be subjected to ALND with its associated 
morbidity. 
In our study, there were no significant differences 
observed when comparing the tumor characteristics 
between the two groups. The exception was lympho-
vascular invasion, which was predictive of patients with 
extensive nodal metastases. This histopathological 
factor needs to be taken into consideration while de-
ciding on ALND following positive sentinel node biopsy 
regardless of the number of positive nodes. 
There was no significant difference in overall sur-
vival between patients with minimal and extensive 
nodal metastasis. It is difficult to be certain whether 
the comparable survival rate achieved translates from 
both groups receiving ALND or being a simple chance 
finding needs to be determined. 
Previous studies have predominantly shown a high 
axillary nodal burden in patients identified from axillary 
ultrasound [24–26]. However, in contrast, our study 
showed that more than one third of patients had minimal 
node involvement (38.6%). These findings are in con-
current with the results obtained by Boland et al. [30], 
who also reports 38.6% of patients had less than three 
positive nodes from ALND. Selection bias may account 
for the high axillary nodal burden documented in the 
literature. Verheuvel et al. [24] explained that axillary 
ultrasound was performed by general radiologists who 
were not specialized in breast cancer and Caudle et al. 
[25] reported that, from 2010, sentinel node-positive 
patients did not undergo axillary dissection and were 
excluded from their study. Reyna et al. [26] reported 
that axillary ultrasound was selectively performed for 
T2 or larger tumors since 2007 and that T1 tumors were 
evaluated according to the preference of the surgeon 
or clinical suspicion. These findings might explain the 
high axillary nodal burden documented in the literature. 
Therefore, based on our study, patients with clinically 
early-stage breast cancer do not have a significant 
axillary burden of disease when they were identified by 
axillary ultrasound with cytology / histology. Similar find-
ings were observed by Cools et al. [27], who reports that 
patients with ultrasound guided biopsy do not harbor 
more nodal metastases than who are not subjected to 
it. Recent meta-analysis by Muneer et al. [28] concurred 
that 43% of patients with positive sentinel lymph node 
biopsy (SLNB) were subjected to unnecessary ALND.
Based on the findings of the Z0011 trial, a significant 
number of patients would have avoided direct axillary 
dissection (11.7% over a period of six years) if they 
had undergone a sentinel lymph node biopsy rather 
than an ultrasound guided FNAC/CB. This is twice the 
number quoted in study by Boland et al. [29] likely due 
to more than half the number of patients undergoing 
mastectomy in their group. 
Additional detail provided on ultrasound, such as 
the number of nodes involved and radiographic features 
of these nodes may further help to identify the patients 
who would benefit from a direct axillary lymph node dis-
section and those patients who should receive sentinel 
lymph node biopsy. Pilewskie et al. [30] stated that 68% 
of patients with more than one abnormal lymph node 
on ultrasound axilla have more than or equal to three 
nodal metastases on ALND. Further research, looking 
at the correlation between radiographic data and axillary 
disease burden, may further help to clarify the patients 
who would be candidates for sentinel lymph node biop-
sy. Radiologists should also be encouraged to clearly 
report the abnormalities detected on ultrasound axilla 
in the light of future studies.
The limitations of our study include biases acquired 
from retrospective analyses and difficulty in reading ul-
trasound reports. This is because of absence of precise 
documentations on ultrasound findings of the axilla in 
relation to number of lymph nodes as there is tendency 
to perform biopsy once abnormal node is identified. Al-
though the sample size of our study is relatively small, it 
strongly advocates that more than one third of patients 
had low-volume nodal metastases, questioning the 
need for ALND in all patients with ultrasound guided 
biopsy proven nodal metastases.
Further prospective studies with novel concepts are 
required to fully ascertain the sub-group of patients who 
can forego axillary lymph node dissection. This could be by 
proceeding directly to SLNB without ultrasound guided bi-
opsy for patients with single abnormal node or by clipping 
the node after positive biopsy and performing SLNB along 
with excision of clipped node rather than ALND. Therefore, 
in the era of Z0011, the role of axillary ultrasound needs 
to be redefined to avoid unnecessary axillary dissection.
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conclusions
Ultrasound with concurrent histology of abnormal 
axillary lymph nodes is currently treated with direct 
ALND and can avoid two stage surgical procedure. 
However, our study shows that more than one third of 
these patients were over-treated and could have spared 
ALND. Hence the role of ultrasound axilla in early breast 
cancer needs to be redefined. 
List of Abbreviations:
FNAC Fine Needle Aspiration Cytology 
CB Core Biopsy
NICE  National Institute for Health and Care Ex-
cellence
ALND  Axillary Lymph Node Dissection 
ACOSOG  American College of Surgeons Oncology 
Group
WLE  Wide Local Excision
HER2  Human Epidermal Growth Factor Receptor 2
ER  Estrogen receptor
PR Progesterone Receptor
SLNB Sentinel Lymph Node Biopsy
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